Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

19 та иш

Иш: Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses

  1. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

    Armand Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim +4

    Мақола201011 иқтибос
    ABI

  2. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

    Shama D. Ahuja, David Ashkin, Monika Avendano +70

    Шарҳ мақола20127 иқтибос
    ABI

  3. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

    Alberto Piubello, Souleymane Hassane Harouna, Mahamadou Bassirou Souleymane +5

    Мақола20146 иқтибос
    ABI

  4. The 2011 update of the World Health Organization guidelines for the programmatic management of drug-resistant tuberculosis

    Dennis Falzon, Ernesto Jaramillo, Holger J. Schünemann

    Мақола20115 иқтибос
    ABI

  5. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients

    K. J. M. Aung, Armand Van Deun, Erik De Clercq +4

    Мақола20145 иқтибос
    ABI

  6. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon

    Christopher Kuaban, J Noeske, Hans L. Rieder +3

    Мақола20155 иқтибос
    ABI

  7. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

    Dennis Falzon, Neel R. Gandhi, Giovanni Battista Migliori +11

    Шарҳ мақола20124 иқтибос
    ABI

  8. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis

    Mayara Lisboa Bastos, Zhiyi Lan, Dick Menzies

    Шарҳ мақола20174 иқтибос
    ABI

  9. Counting Pyrazinamide in Regimens for Multidrug-Resistant Tuberculosis

    Molly F. Franke, Mercedes C. Becerra, Dylan B. Tierney +5

    Мақола20153 иқтибос
    ABI

  10. Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance

    J. Peter Cegielski, Ekaterina V. Kurbatova, Martie van der Walt +74

    Мақола20153 иқтибос
    ABI

  11. The binomial distribution of meta-analysis was preferred to model within-study variability

    Taye H. Hamza, Hans C. van Houwelingen, Theo Stijnen

    Мақола20072 иқтибос
    ABI

  12. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis

    Giovanni Battista Migliori, Giovanni Sotgiu, Neel R. Gandhi +16

    Шарҳ мақола20122 иқтибос
    ABI

  13. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis

    Giovanni Sotgiu, Simon Tiberi, Lia D’Ambrosio +3

    Мақола20162 иқтибос
    ABI

  14. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis

    Giovanni Sotgiu, Simon Tiberi, Lia D’Ambrosio +18

    Бошқа20162 иқтибос
    ABI

  15. Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations

    Francis Varaine, Lorenzo Guglielmetti, Helena Huerga +5

    Бошқа20162 иқтибос
    ABI

  16. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  17. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  18. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  19. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI